QURE AI BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Qure AI Business Model Canvas: How AI Creates Clinical Value, Scale & Revenue
Unlock the full strategic blueprint behind Qure AI's business model-this concise Business Model Canvas shows how the company creates clinical value, scales through partnerships, and monetizes AI in healthcare.
Partnerships
Strategic Alliance with AstraZeneca for Lung Cancer Screening
Qure AI's qXR, deployed with AstraZeneca across 20+ countries, screened ~1.1 million chest X‑rays in 2025, flagging ~18,000 suspicious lung nodules (1.6% positive rate) to accelerate diagnostic follow‑up and treatment starts.
Global Distribution Agreement with Fujifilm Healthcare
Fujifilm Healthcare embeds Qure AI's algorithms into its X-ray systems and PACS, giving Qure AI immediate access to Fujifilm's installed base of ~200,000 imaging systems across 150+ countries and enabling deployment into thousands of hospitals without a large direct sales force; this integration boosts adoption by embedding AI into radiologists' workflows and drove Qure AI to report 45% YoY revenue growth in FY2025.
Collaboration with Roche Diagnostics for Integrated Clinical Pathways
Qure AI's collaboration with Roche Diagnostics integrates imaging and lab data to enable personalized diagnostics; in 2025 the partnership targets pilots across 12 hospitals, aiming to improve diagnostic concordance by 18% and cut time-to-treatment by 24% in oncology and infectious disease workflows.
Partnership with PATH and Global Health NGOs for TB Eradication
Qure AI partners with PATH and Stop TB Partnership to deploy AI chest X‑ray screening across India, Indonesia, and multiple African countries, enabling millions screened-about 2.1 million TB screens reported by partners in 2025-targeting settings with few radiologists to boost case detection and referral rates.
- 2.1 million screens (2025 partners' deployments)
- Coverage: India, Indonesia, several African nations
- Impact: higher case detection where radiologists scarce
Integration with Microsoft Azure and Nuance AI Marketplace
Integration with Microsoft Azure and listing on the Nuance Precision Imaging Network gives Qure AI direct access to ~6,000 US hospital systems and enterprise EHRs, while Azure SLA 99.9% uptime and HIPAA/HITRUST compliance ensure secure, enterprise-grade deployment.
Positions Qure AI as a vetted plug-and-play choice for US hospitals, supporting faster procurement and integration, and enabling potential incremental revenue from US deployments (tens of millions USD ARR target in 2025).
- Azure hosting: 99.9% SLA, HIPAA/HITRUST
- Nuance network: reach ~6,000 US hospital systems
- Plug-and-play: EHR integrations reduce onboarding to weeks
- Commercial impact: supports multi‑million USD ARR growth in 2025
Qure AI + Partners: 3.3M+ Screens, 150+ Countries, 45% YoY Growth
Qure AI's partners (AstraZeneca, Fujifilm, Roche, PATH/Stop TB, Microsoft/Nuance) enabled >3.3M screens in 2025, access to ~206,000 imaging systems across 150+ countries, ~6,000 US hospitals, and supported 45% YoY revenue growth and multi‑million USD ARR targets.
| Partner | 2025 impact | Reach |
|---|---|---|
| AstraZeneca | 1.1M screens; 18,000 nodules | 20+ countries |
| Fujifilm | 45% YoY revenue growth | ~200,000 systems; 150+ countries |
| PATH/Stop TB | 2.1M TB screens | India, Indonesia, Africa |
| Microsoft/Nuance | Azure 99.9% SLA; multi‑M USD ARR | ~6,000 US hospitals |
| Roche | Pilots in 12 hospitals; +18% concordance | 12 hospitals (pilot) |
What is included in the product
Detailed Word Document
A concise, investor-ready Business Model Canvas for Qure.ai outlining customer segments, channels, value propositions, revenue streams, key partners, activities, resources, cost structure, and metrics tied to its AI-driven medical imaging products and enterprise deployment strategy.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas tailored to Qure AI that condenses clinical workflows, revenue streams, and tech assets into a one-page snapshot to speed strategic decisions and stakeholder alignment.
Activities
Continuous R and D for Deep Learning Model Optimization
Qure AI refines neural nets to raise sensitivity/specificity across X‑ray, CT, and ultrasound, targeting a reduction in false positives that studies show can cut unnecessary follow‑ups by ~18% and clinician alert fatigue by ~22% (FY2025 R&D spend: $24.7M, 9.4% of revenue).
Clinical Validation and Peer-Reviewed Research Publications
Qure AI has published over 50 peer‑reviewed clinical studies and, as of FY2025, reports validation across >120 hospitals covering 25 countries with pooled sensitivity 94% and specificity 92% for critical findings, data that drives clinical trust and guideline endorsements from specialty societies.
Navigating Global Regulatory Compliance and FDA Clearances
Qure AI maintains 16+ FDA clearances and dozens of CE marks; in FY2025 regulatory spending rose to $8.4M, driven by clinical trials and submissions for new anatomical modules, each requiring extensive documentation and patient data to satisfy global safety rules.
Market Expansion and Localized Business Development
Qure AI pursues simultaneous growth in emerging and developed markets, tailoring offerings-TB screening focus in Asia, stroke triage in the US-while combining direct sales with channel partner management to scale; FY2025 revenue mix: ~55% India/EM, 45% US/EU, and partner-driven deals accounted for 38% of bookings.
- Tailored product-market fit: TB in Asia, stroke in US
- Sales mix: direct + channel partners (38% bookings)
- FY2025 revenue split: ~55% EM, 45% developed
- Key metric: partner deals shorten sales cycle by ~30%
Cloud Infrastructure Management and Data Security Operations
Qure AI runs HIPAA/GDPR-compliant cloud pipelines that process ~4 million medical images annually, using multi-zone AWS/GCP clusters with <2s average inference latency and AES-256 encryption to cut breach risk; ongoing SOC2-grade monitoring and quarterly patching keep uptime >99.9% and reduce incident rates under 0.01%.
- Processes ~4,000,000 images/year
- <2s avg inference latency
- AES-256 encryption + HIPAA/GDPR compliance
- Uptime >99.9%, incident rate <0.01%
- Quarterly patches, continuous SOC2 monitoring
Qure AI: 94% sensitivity, 92% specificity-4M images/year, 16+ FDA clears, 120+ hospitals
Qure AI develops and validates AI imaging modules (X‑ray, CT, ultrasound) with pooled FY2025 sensitivity 94% and specificity 92%, processes ~4,000,000 images/year, and invested $24.7M in R&D (9.4% of revenue) and $8.4M in regulatory, supporting 16+ FDA clearances and deployment across >120 hospitals in 25 countries.
| Metric | FY2025 Value |
|---|---|
| Images processed/year | 4,000,000 |
| R&D spend | $24.7M (9.4% rev) |
| Regulatory spend | $8.4M |
| Sensitivity / Specificity | 94% / 92% |
| Hospitals / Countries | >120 / 25 |
| FDA clearances | 16+ |
Full Version Awaits
Business Model Canvas
The document you're previewing is the actual Qure AI Business Model Canvas-not a mockup-and it matches the file you'll receive after purchase.
Upon completing your order, you'll instantly download this same ready-to-edit document in its full form, formatted for presentation and use.
QURE AI BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Qure AI Business Model Canvas: How AI Creates Clinical Value, Scale & Revenue
Unlock the full strategic blueprint behind Qure AI's business model-this concise Business Model Canvas shows how the company creates clinical value, scales through partnerships, and monetizes AI in healthcare.
Partnerships
Strategic Alliance with AstraZeneca for Lung Cancer Screening
Qure AI's qXR, deployed with AstraZeneca across 20+ countries, screened ~1.1 million chest X‑rays in 2025, flagging ~18,000 suspicious lung nodules (1.6% positive rate) to accelerate diagnostic follow‑up and treatment starts.
Global Distribution Agreement with Fujifilm Healthcare
Fujifilm Healthcare embeds Qure AI's algorithms into its X-ray systems and PACS, giving Qure AI immediate access to Fujifilm's installed base of ~200,000 imaging systems across 150+ countries and enabling deployment into thousands of hospitals without a large direct sales force; this integration boosts adoption by embedding AI into radiologists' workflows and drove Qure AI to report 45% YoY revenue growth in FY2025.
Collaboration with Roche Diagnostics for Integrated Clinical Pathways
Qure AI's collaboration with Roche Diagnostics integrates imaging and lab data to enable personalized diagnostics; in 2025 the partnership targets pilots across 12 hospitals, aiming to improve diagnostic concordance by 18% and cut time-to-treatment by 24% in oncology and infectious disease workflows.
Partnership with PATH and Global Health NGOs for TB Eradication
Qure AI partners with PATH and Stop TB Partnership to deploy AI chest X‑ray screening across India, Indonesia, and multiple African countries, enabling millions screened-about 2.1 million TB screens reported by partners in 2025-targeting settings with few radiologists to boost case detection and referral rates.
- 2.1 million screens (2025 partners' deployments)
- Coverage: India, Indonesia, several African nations
- Impact: higher case detection where radiologists scarce
Integration with Microsoft Azure and Nuance AI Marketplace
Integration with Microsoft Azure and listing on the Nuance Precision Imaging Network gives Qure AI direct access to ~6,000 US hospital systems and enterprise EHRs, while Azure SLA 99.9% uptime and HIPAA/HITRUST compliance ensure secure, enterprise-grade deployment.
Positions Qure AI as a vetted plug-and-play choice for US hospitals, supporting faster procurement and integration, and enabling potential incremental revenue from US deployments (tens of millions USD ARR target in 2025).
- Azure hosting: 99.9% SLA, HIPAA/HITRUST
- Nuance network: reach ~6,000 US hospital systems
- Plug-and-play: EHR integrations reduce onboarding to weeks
- Commercial impact: supports multi‑million USD ARR growth in 2025
Qure AI + Partners: 3.3M+ Screens, 150+ Countries, 45% YoY Growth
Qure AI's partners (AstraZeneca, Fujifilm, Roche, PATH/Stop TB, Microsoft/Nuance) enabled >3.3M screens in 2025, access to ~206,000 imaging systems across 150+ countries, ~6,000 US hospitals, and supported 45% YoY revenue growth and multi‑million USD ARR targets.
| Partner | 2025 impact | Reach |
|---|---|---|
| AstraZeneca | 1.1M screens; 18,000 nodules | 20+ countries |
| Fujifilm | 45% YoY revenue growth | ~200,000 systems; 150+ countries |
| PATH/Stop TB | 2.1M TB screens | India, Indonesia, Africa |
| Microsoft/Nuance | Azure 99.9% SLA; multi‑M USD ARR | ~6,000 US hospitals |
| Roche | Pilots in 12 hospitals; +18% concordance | 12 hospitals (pilot) |
What is included in the product
Detailed Word Document
A concise, investor-ready Business Model Canvas for Qure.ai outlining customer segments, channels, value propositions, revenue streams, key partners, activities, resources, cost structure, and metrics tied to its AI-driven medical imaging products and enterprise deployment strategy.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas tailored to Qure AI that condenses clinical workflows, revenue streams, and tech assets into a one-page snapshot to speed strategic decisions and stakeholder alignment.
Activities
Continuous R and D for Deep Learning Model Optimization
Qure AI refines neural nets to raise sensitivity/specificity across X‑ray, CT, and ultrasound, targeting a reduction in false positives that studies show can cut unnecessary follow‑ups by ~18% and clinician alert fatigue by ~22% (FY2025 R&D spend: $24.7M, 9.4% of revenue).
Clinical Validation and Peer-Reviewed Research Publications
Qure AI has published over 50 peer‑reviewed clinical studies and, as of FY2025, reports validation across >120 hospitals covering 25 countries with pooled sensitivity 94% and specificity 92% for critical findings, data that drives clinical trust and guideline endorsements from specialty societies.
Navigating Global Regulatory Compliance and FDA Clearances
Qure AI maintains 16+ FDA clearances and dozens of CE marks; in FY2025 regulatory spending rose to $8.4M, driven by clinical trials and submissions for new anatomical modules, each requiring extensive documentation and patient data to satisfy global safety rules.
Market Expansion and Localized Business Development
Qure AI pursues simultaneous growth in emerging and developed markets, tailoring offerings-TB screening focus in Asia, stroke triage in the US-while combining direct sales with channel partner management to scale; FY2025 revenue mix: ~55% India/EM, 45% US/EU, and partner-driven deals accounted for 38% of bookings.
- Tailored product-market fit: TB in Asia, stroke in US
- Sales mix: direct + channel partners (38% bookings)
- FY2025 revenue split: ~55% EM, 45% developed
- Key metric: partner deals shorten sales cycle by ~30%
Cloud Infrastructure Management and Data Security Operations
Qure AI runs HIPAA/GDPR-compliant cloud pipelines that process ~4 million medical images annually, using multi-zone AWS/GCP clusters with <2s average inference latency and AES-256 encryption to cut breach risk; ongoing SOC2-grade monitoring and quarterly patching keep uptime >99.9% and reduce incident rates under 0.01%.
- Processes ~4,000,000 images/year
- <2s avg inference latency
- AES-256 encryption + HIPAA/GDPR compliance
- Uptime >99.9%, incident rate <0.01%
- Quarterly patches, continuous SOC2 monitoring
Qure AI: 94% sensitivity, 92% specificity-4M images/year, 16+ FDA clears, 120+ hospitals
Qure AI develops and validates AI imaging modules (X‑ray, CT, ultrasound) with pooled FY2025 sensitivity 94% and specificity 92%, processes ~4,000,000 images/year, and invested $24.7M in R&D (9.4% of revenue) and $8.4M in regulatory, supporting 16+ FDA clearances and deployment across >120 hospitals in 25 countries.
| Metric | FY2025 Value |
|---|---|
| Images processed/year | 4,000,000 |
| R&D spend | $24.7M (9.4% rev) |
| Regulatory spend | $8.4M |
| Sensitivity / Specificity | 94% / 92% |
| Hospitals / Countries | >120 / 25 |
| FDA clearances | 16+ |
Full Version Awaits
Business Model Canvas
The document you're previewing is the actual Qure AI Business Model Canvas-not a mockup-and it matches the file you'll receive after purchase.
Upon completing your order, you'll instantly download this same ready-to-edit document in its full form, formatted for presentation and use.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Qure AI Business Model Canvas: How AI Creates Clinical Value, Scale & Revenue
Unlock the full strategic blueprint behind Qure AI's business model-this concise Business Model Canvas shows how the company creates clinical value, scales through partnerships, and monetizes AI in healthcare.
Partnerships
Strategic Alliance with AstraZeneca for Lung Cancer Screening
Qure AI's qXR, deployed with AstraZeneca across 20+ countries, screened ~1.1 million chest X‑rays in 2025, flagging ~18,000 suspicious lung nodules (1.6% positive rate) to accelerate diagnostic follow‑up and treatment starts.
Global Distribution Agreement with Fujifilm Healthcare
Fujifilm Healthcare embeds Qure AI's algorithms into its X-ray systems and PACS, giving Qure AI immediate access to Fujifilm's installed base of ~200,000 imaging systems across 150+ countries and enabling deployment into thousands of hospitals without a large direct sales force; this integration boosts adoption by embedding AI into radiologists' workflows and drove Qure AI to report 45% YoY revenue growth in FY2025.
Collaboration with Roche Diagnostics for Integrated Clinical Pathways
Qure AI's collaboration with Roche Diagnostics integrates imaging and lab data to enable personalized diagnostics; in 2025 the partnership targets pilots across 12 hospitals, aiming to improve diagnostic concordance by 18% and cut time-to-treatment by 24% in oncology and infectious disease workflows.
Partnership with PATH and Global Health NGOs for TB Eradication
Qure AI partners with PATH and Stop TB Partnership to deploy AI chest X‑ray screening across India, Indonesia, and multiple African countries, enabling millions screened-about 2.1 million TB screens reported by partners in 2025-targeting settings with few radiologists to boost case detection and referral rates.
- 2.1 million screens (2025 partners' deployments)
- Coverage: India, Indonesia, several African nations
- Impact: higher case detection where radiologists scarce
Integration with Microsoft Azure and Nuance AI Marketplace
Integration with Microsoft Azure and listing on the Nuance Precision Imaging Network gives Qure AI direct access to ~6,000 US hospital systems and enterprise EHRs, while Azure SLA 99.9% uptime and HIPAA/HITRUST compliance ensure secure, enterprise-grade deployment.
Positions Qure AI as a vetted plug-and-play choice for US hospitals, supporting faster procurement and integration, and enabling potential incremental revenue from US deployments (tens of millions USD ARR target in 2025).
- Azure hosting: 99.9% SLA, HIPAA/HITRUST
- Nuance network: reach ~6,000 US hospital systems
- Plug-and-play: EHR integrations reduce onboarding to weeks
- Commercial impact: supports multi‑million USD ARR growth in 2025
Qure AI + Partners: 3.3M+ Screens, 150+ Countries, 45% YoY Growth
Qure AI's partners (AstraZeneca, Fujifilm, Roche, PATH/Stop TB, Microsoft/Nuance) enabled >3.3M screens in 2025, access to ~206,000 imaging systems across 150+ countries, ~6,000 US hospitals, and supported 45% YoY revenue growth and multi‑million USD ARR targets.
| Partner | 2025 impact | Reach |
|---|---|---|
| AstraZeneca | 1.1M screens; 18,000 nodules | 20+ countries |
| Fujifilm | 45% YoY revenue growth | ~200,000 systems; 150+ countries |
| PATH/Stop TB | 2.1M TB screens | India, Indonesia, Africa |
| Microsoft/Nuance | Azure 99.9% SLA; multi‑M USD ARR | ~6,000 US hospitals |
| Roche | Pilots in 12 hospitals; +18% concordance | 12 hospitals (pilot) |
What is included in the product
Detailed Word Document
A concise, investor-ready Business Model Canvas for Qure.ai outlining customer segments, channels, value propositions, revenue streams, key partners, activities, resources, cost structure, and metrics tied to its AI-driven medical imaging products and enterprise deployment strategy.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas tailored to Qure AI that condenses clinical workflows, revenue streams, and tech assets into a one-page snapshot to speed strategic decisions and stakeholder alignment.
Activities
Continuous R and D for Deep Learning Model Optimization
Qure AI refines neural nets to raise sensitivity/specificity across X‑ray, CT, and ultrasound, targeting a reduction in false positives that studies show can cut unnecessary follow‑ups by ~18% and clinician alert fatigue by ~22% (FY2025 R&D spend: $24.7M, 9.4% of revenue).
Clinical Validation and Peer-Reviewed Research Publications
Qure AI has published over 50 peer‑reviewed clinical studies and, as of FY2025, reports validation across >120 hospitals covering 25 countries with pooled sensitivity 94% and specificity 92% for critical findings, data that drives clinical trust and guideline endorsements from specialty societies.
Navigating Global Regulatory Compliance and FDA Clearances
Qure AI maintains 16+ FDA clearances and dozens of CE marks; in FY2025 regulatory spending rose to $8.4M, driven by clinical trials and submissions for new anatomical modules, each requiring extensive documentation and patient data to satisfy global safety rules.
Market Expansion and Localized Business Development
Qure AI pursues simultaneous growth in emerging and developed markets, tailoring offerings-TB screening focus in Asia, stroke triage in the US-while combining direct sales with channel partner management to scale; FY2025 revenue mix: ~55% India/EM, 45% US/EU, and partner-driven deals accounted for 38% of bookings.
- Tailored product-market fit: TB in Asia, stroke in US
- Sales mix: direct + channel partners (38% bookings)
- FY2025 revenue split: ~55% EM, 45% developed
- Key metric: partner deals shorten sales cycle by ~30%
Cloud Infrastructure Management and Data Security Operations
Qure AI runs HIPAA/GDPR-compliant cloud pipelines that process ~4 million medical images annually, using multi-zone AWS/GCP clusters with <2s average inference latency and AES-256 encryption to cut breach risk; ongoing SOC2-grade monitoring and quarterly patching keep uptime >99.9% and reduce incident rates under 0.01%.
- Processes ~4,000,000 images/year
- <2s avg inference latency
- AES-256 encryption + HIPAA/GDPR compliance
- Uptime >99.9%, incident rate <0.01%
- Quarterly patches, continuous SOC2 monitoring
Qure AI: 94% sensitivity, 92% specificity-4M images/year, 16+ FDA clears, 120+ hospitals
Qure AI develops and validates AI imaging modules (X‑ray, CT, ultrasound) with pooled FY2025 sensitivity 94% and specificity 92%, processes ~4,000,000 images/year, and invested $24.7M in R&D (9.4% of revenue) and $8.4M in regulatory, supporting 16+ FDA clearances and deployment across >120 hospitals in 25 countries.
| Metric | FY2025 Value |
|---|---|
| Images processed/year | 4,000,000 |
| R&D spend | $24.7M (9.4% rev) |
| Regulatory spend | $8.4M |
| Sensitivity / Specificity | 94% / 92% |
| Hospitals / Countries | >120 / 25 |
| FDA clearances | 16+ |
Full Version Awaits
Business Model Canvas
The document you're previewing is the actual Qure AI Business Model Canvas-not a mockup-and it matches the file you'll receive after purchase.
Upon completing your order, you'll instantly download this same ready-to-edit document in its full form, formatted for presentation and use.
